Dr. David E. Einspahr
Claim this profileCotton O'Neil Cancer Center / Stormont Vail Health
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
31 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Stage II
Stage I
Stage III
Affiliated Hospitals
Clinical Trials David E. Einspahr is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about David E. Einspahr
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David E. Einspahr has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Pemetrexed Disodium
- Gemcitabine Hydrochloride
- Gemcitabine
Breakdown of trials David E. Einspahr has run
Lung Cancer
Non-Small Cell Lung Cancer
Skin Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David E. Einspahr specialize in?
David E. Einspahr focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is David E. Einspahr currently recruiting for clinical trials?
Yes, David E. Einspahr is currently recruiting for 4 clinical trials in Topeka Kansas. If you're interested in participating, you should apply.
Are there any treatments that David E. Einspahr has studied deeply?
Yes, David E. Einspahr has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with David E. Einspahr?
Apply for one of the trials that David E. Einspahr is conducting.
What is the office address of David E. Einspahr?
The office of David E. Einspahr is located at: Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas 66606 United States. This is the address for their practice at the Cotton O'Neil Cancer Center / Stormont Vail Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.